Calmark receives recurring orders from Greece

Calmark Sweden AB announced today that they have received a repeat order from the distributor Prime Bioscience in Greece. Today's order has a smaller financial value, but is important from a launch perspective.

Use of capillary sampling, as press release 240130, is an important factor for the Greek market. The interest in Calmark's Neo-Bilirubin product is big and now being able to also use capillary samples facilitates the launch.

"Our collaboration with Prime Bioscience in Greece is very good. We are happy that there are recurring orders from them and that the launch is progressing," comments CEO Anna Söderlund.

Every care has been taken in the translation of this document. In the event of discrepancies, the Swedish original will supersede the English translation.

For more information about Calmark Sweden AB, please contact:

Anna Söderlund, CEO
Telefon: +46 70 214 98 93
E-post: anna.soderlund@calmark.se 
www.calmark.se 

Calmark Sweden AB is a medical technology company that manufactures and markets a point-of-care (POC) analysis method with easier and faster diagnostics of medical conditions in newborns. The unique test platform consists of a portable instrument and test cassettes for various biomarkers. The first test, Neo-Bilirubin, is CE marked and measures the bilirubin level in whole blood for jaundice detection in newborns. In the Western world, the introduction of POC diagnostics is resulting in huge savings and shorter care chains. In less developed healthcare systems, the product offers a decision support which is currently lacking, since the access to hospital laboratories often is limited. Calmark aims to become the global leader in POC diagnostics for newborns and, in the long term, to offer all relevant tests for the first period of life. The B share is listed on the Spotlight Stock Market and is traded under the CALMA B ticker. Read more at www.calmark.se/eng/home.  

Tags: